Difference between revisions of "Meningioma"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "www.ncbi.nlm.nih.gov/pubmed" to "pubmed.ncbi.nlm.nih.gov") Tags: mobile edit mobile web edit |
|||
| Line 16: | Line 16: | ||
==EANO== | ==EANO== | ||
| − | *'''2016:''' [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30321-7/fulltext EANO guidelines for the diagnosis and treatment of meningiomas] [https:// | + | *'''2016:''' [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30321-7/fulltext EANO guidelines for the diagnosis and treatment of meningiomas] [https://pubmed.ncbi.nlm.nih.gov/27599143 PubMed] |
==[https://www.nccn.org/ NCCN]== | ==[https://www.nccn.org/ NCCN]== | ||
| Line 44: | Line 44: | ||
===References=== | ===References=== | ||
| − | # '''SWOG S9005:''' Ji Y, Rankin C, Grunberg S, Sherrod AE, Ahmadi J, Townsend JJ, Feun LG, Fredericks RK, Russell CA, Kabbinavar FF, Stelzer KJ, Schott A, Verschraegen C. Double-blind phase III randomized trial of the antiprogestin agent mifepristone in the treatment of unresectable meningioma: SWOG S9005. J Clin Oncol. 2015 Dec 1;33(34):4093-8. Epub 2015 Nov 2. [https://ascopubs.org/doi/full/10.1200/JCO.2015.61.6490 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4669593/ link to PMC article] [https:// | + | # '''SWOG S9005:''' Ji Y, Rankin C, Grunberg S, Sherrod AE, Ahmadi J, Townsend JJ, Feun LG, Fredericks RK, Russell CA, Kabbinavar FF, Stelzer KJ, Schott A, Verschraegen C. Double-blind phase III randomized trial of the antiprogestin agent mifepristone in the treatment of unresectable meningioma: SWOG S9005. J Clin Oncol. 2015 Dec 1;33(34):4093-8. Epub 2015 Nov 2. [https://ascopubs.org/doi/full/10.1200/JCO.2015.61.6490 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4669593/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/26527781 PubMed] |
[[Category:Meningioma regimens]] | [[Category:Meningioma regimens]] | ||
[[Category:Disease-specific pages]] | [[Category:Disease-specific pages]] | ||
[[Category:CNS cancers]] | [[Category:CNS cancers]] | ||
Revision as of 02:04, 25 February 2020
| Section editor | |
|---|---|
 |
Seema Nagpal, MD Stanford University Palo Alto, CA |
0 regimens on this page
0 variants on this page
|
Guidelines
EANO
NCCN
Unresectable, all lines of therapy
Placebo
| back to top |
Regimen
| Study | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|
| Ji et al. 2015 (SWOG S9005) | Phase III (C) | Mifepristone | Did not meet primary endpoint of FFS |
No active antineoplastic treatment.
References
- SWOG S9005: Ji Y, Rankin C, Grunberg S, Sherrod AE, Ahmadi J, Townsend JJ, Feun LG, Fredericks RK, Russell CA, Kabbinavar FF, Stelzer KJ, Schott A, Verschraegen C. Double-blind phase III randomized trial of the antiprogestin agent mifepristone in the treatment of unresectable meningioma: SWOG S9005. J Clin Oncol. 2015 Dec 1;33(34):4093-8. Epub 2015 Nov 2. link to original article link to PMC article PubMed